Perspective: Patents, post-MedImmune

[NOTE: This article inaugurates our “Perspective” feature, in which entrepreneurs, investors, and other experts discuss developments or pressing issues within the life sciences -- a parallel effort to the "Contributors" section on the main VentureBeat page. We ultimately hope to distinguish perspective pieces from our regular coverage with a distinctive font and other visual elements, but for now, they'll just be labeled clearly and will carry a note much like this one. --D.P.H.]